Apple Watch getting redesigned blood oxygen feature following legal dispute

Apple has reintroduced a redesigned blood oxygen monitoring feature for select Apple Watch Series 9, Series 10, and Ultra 2 models, enabled by a recent U.S. Customs ruling. This development resolves a years-long intellectual property dispute with medical technology firm Masimo, which previously led to an International Trade Commission infringement finding and Apple pausing sales or removing the feature from affected watches. The restoration of this key health capability reinforces Apple's strategic commitment to expanding its presence in the health and wellness technology sector.

Analysis

Apple has effectively navigated a significant legal and product-level challenge by reintroducing a redesigned blood oxygen feature for its latest Apple Watch models. This move follows a U.S. Customs ruling that allows the company to circumvent an International Trade Commission (ITC) import ban, which was imposed after a finding of patent infringement on technology from Masimo (MASI). For Apple, this is a material positive development, as it restores a key health-monitoring function that is central to its wearables' value proposition and its broader strategic push into the healthcare sector. The successful redesign mitigates a competitive disadvantage and removes an operational overhang that had previously forced the company to halt sales and then sell modified devices. For Masimo, this outcome represents a setback; while its patent was validated by the ITC, Apple's ability to engineer a workaround diminishes Masimo's leverage and the potential for a significant royalty or settlement agreement from this specific litigation.

Key Decisions for Investors

• Investors in Apple should view the resolution of the blood oxygen feature issue as a de-risking event for the wearables segment, reinforcing the company's long-term growth narrative in health technology.
• Holders of Masimo should reassess the expected financial upside from its litigation against Apple, as this development demonstrates Apple's capacity to innovate around patent disputes, potentially limiting future royalty streams.
• It is prudent to monitor Apple's upcoming quarterly reports for any commentary on Apple Watch sales to gauge if the feature's restoration accelerates adoption, and to watch for further legal maneuvers from Masimo.